1
Pyxis Oncology
Oncology
HBM contact: Dr Ivo Staijen, Dr Emil Bujak
Company status: public
Pyxis is developing a differentiated
portfolio of biologics, including antibody-drug conjugates (ADCs) and
immunotherapies, to improve the lives of patients with difficult-to-treat
cancers.